Glenmark Pharmaceuticals Limited – FDA 483, Jun 22, 2022
Glenmark Pharmaceuticals Limited, a non-sterile finished drug manufacturer in Baddi, India, was cited for six observations during an FDA inspection. Key issues include failures to thoroughly review discrepancies and batch failures, inadequate equipment cleaning and maintenance, unsubmitted Field Alert Reports for failing products, and insufficient written procedures for process controls. These findings indicate significant concerns regarding quality control, process validation, and data integrity.
ID · bbfcf848-0ee0-45ac-a30f-6b77a402de44
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.